Wed, July 24, 2024

Avidity Biosciences’ Stock Surges 20% After FSHD Study Results

WHO reported delta is the fastest and fittest COVID strain

Quick Look:

  • Avidity Biosciences’ del-brax treatment shows over 50% reduction in DUX4 protein in FSHD patients.
  • Significant muscle strength and function improvements highlight the treatment’s efficacy.
  • Avidity’s stock price rose over 20% post-announcement, reflecting strong investor confidence.

Avidity Biosciences (RNA) recently announced groundbreaking study results. The research focused on its novel treatment for a rare form of muscular dystrophy. It sends ripples through the scientific and financial communities. The treatment, known as del-Brax, has demonstrated significant efficacy in tackling facioscapulohumeral muscular dystrophy (FSHD), a condition marked by progressive muscle weakening.

Study Shows 50% Average DUX4 Reduction in 4 Months

Over four months, the study revealed that patients treated with del-brax experienced an average reduction of more than 50% in DUX4. This is a protein linked to the deterioration observed in FSHD. Impressively, all patients reported a minimum reduction of 20%. These results underscore the potential of del-Brax to alter the course of FSHD substantially.

Besides, the clinical trial highlighted notable improvements in upper and lower limb strength. Moreover, the treatment enhanced overall muscle function compared to a placebo group and the natural progression of the disease. These findings indicate that targeting DUX4 can yield functional benefits within a relatively short timeframe. Therefore underscoring Avidity Biosciences’ meticulous research and development efforts.

Avidity Biosciences Stock Climbs Over 20%, Reaches £35.03

Following the announcement, Avidity Biosciences witnessed a premarket stock surge of over 20%, reaching a new price of £35.03 per share. The company’s performance over the past year has been stellar, with shares ranking in the top 1% of all stocks. Investors have responded positively to the robust data, reflecting confidence in the company’s strategic direction and innovative pipeline.

The Phase 1/2 FORTITUDE trial, involving 39 participants with FSHD, served as the foundation for these promising results. The trial helped to evaluate the safety and efficacy of del-brax. The data revealed substantial reductions in DUX4 levels, with functional improvements observed across the patient cohort. Moreover, del-Brax was well tolerated, suggesting a favourable safety profile.

Medical Community Praises 50% DUX4 Reduction in FSHD Study

The results from the FORTITUDE trial have been met with enthusiasm within the medical community. Mark Stone, President and CEO of the FSHD Society highlighted the significance of the findings, noting that they offer hope for individuals living with FSHD. The disease’s progression can severely impact daily activities, work, and social interactions, making these positive outcomes particularly noteworthy.

Avidity Biosciences’ FSHD Study: 50% DUX4 Reduction, Stock Up 20%

Avidity Biosciences’ recent study results mark a significant milestone in treating FSHD. Furthermore, the impressive reductions in DUX4 levels and associated functional improvements provide hope for patients. The company’s rigorous approach and innovative strategies have advanced scientific understanding and bolstered investor confidence, as reflected in the remarkable surge in its stock value. As Avidity continues to push the boundaries of medical research, its contributions to combating muscular dystrophy promise a brighter future for many affected individuals.


The Greenback: A pile of Canadian dollar bills.

Quick Look: Oil Prices Impact: The slump in crude oil prices weakens

Treasury stock

Quick Look: The S&P 500 and Dow Jones slipped by ~0.2% and


Quick Look: Ether ETFs launched with over $1 billion in trading volume


Leave a Comment

Your email address will not be published. Required fields are marked *

User Review
  • Support
  • Platform
  • Spreads
  • Trading Instument